Shandong Boan Biotechnology Co (FRA:UJ9) Retained Earnings: €-67.18 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UJ9 Shandong Boan Biotechnology Co Ltd FRA:UJ9
44 GF Score
Price €0.48
GF Value €1.77
! 5 Warning Signs
View Full Analysis

What is Shandong Boan Biotechnology Co Retained Earnings?

Shandong Boan Biotechnology Co FRA:UJ9 -3.23% 44 Retained Earnings is €-67.18 Mil as of Dec. 2025. GuruFocus rates FRA:UJ9 with a GF Score™ of 44/100 and a GF Value™ of €1.77. The stock has 5 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Shandong Boan Biotechnology Co's retained earnings for the quarter that ended in Dec. 2025 was €-67.18 Mil.

Shandong Boan Biotechnology Co's quarterly retained earnings increased from Dec. 2024 (€-73.36 Mil) to Jun. 2025 (€-65.19 Mil) but then declined from Jun. 2025 (€-65.19 Mil) to Dec. 2025 (€-67.18 Mil).

Shandong Boan Biotechnology Co's annual retained earnings increased from Dec. 2023 (€-81.05 Mil) to Dec. 2024 (€-73.36 Mil) and increased from Dec. 2024 (€-73.36 Mil) to Dec. 2025 (€-67.18 Mil).


Shandong Boan Biotechnology Co  (FRA:UJ9) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Shandong Boan Biotechnology Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Shandong Boan Biotechnology Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co Retained Earnings Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -24.47 -69.20 -81.05 -73.36 -67.18

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -81.05 -72.98 -73.36 -65.19 -67.18
FRA:UJ9
44GF Score
Shandong Boan Biotechnology Co Ltd FRA:UJ9
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Boan Biotechnology Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-67.18 Mil mean?
Shandong Boan Biotechnology Co (FRA:UJ9) has a Retained Earnings of €-67.18 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Shandong Boan Biotechnology Co and its competitors.
Is Shandong Boan Biotechnology Co's Retained Earnings too high?
Shandong Boan Biotechnology Co's current Retained Earnings is €-67.18 Mil. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Retained Earnings compare to VRTX and REGN?
Shandong Boan Biotechnology Co's Retained Earnings of €-67.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current Retained Earnings is €-67.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Retained Earnings of €-67.18 Mil. The stock's GF Value™ is €1.77, compared to a current price of €0.48 — trading 72.9% below its estimated fair value. The current Retained Earnings is €-67.18 Mil. Shandong Boan Biotechnology Co's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Retained Earnings is €-67.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued. The current stock price of €0.48 is trading 72.9% below its estimated GF Value™ of €1.77.

Key valuation signals for FRA:UJ9:

  • Retained Earnings: €-67.18 Mil
  • GF Value™: €1.77 vs. price of €0.48 (72.9% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shandong Boan Biotechnology Co Business Description

Other Exchanges 06955:Hong Kong
Address No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score

Get the complete analysis for FRA:UJ9

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€1.77
GF Value